Results 101 to 110 of about 4,689 (214)

Evaluating the Potential of Microdosing 1cp‐LSD for the Treatment of Canine Anxiety: A One‐Month Case Study

Veterinary Medicine and Science
This pilot study explored the potential of microdosing 1‐cyclopropionyl‐d‐lysergic acid diethylamide (1cp‐LSD) to treat canine anxiety. A single‐case study was conducted on a 13‐year‐old female dog with severe separation anxiety, who was treated with 5 ...
Elisa Hernández‐Álvarez, Lucas F. Borkel, Jaime Rojas‐Hernández, Domingo J. Quintana‐Hernández, Ignacio García‐Serrano, Tobías Fernández‐Borkel, Manuel Zumbado, Luis Alberto Henríquez‐Hernández   +7 more
doaj   +1 more source

Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. [PDF]

Neuropsychopharmacology, 2023
Glazer J, Murray CH, Nusslock R, Lee R, de Wit H.   +4 more
europepmc   +1 more source

Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). [PDF]

J Psychopharmacol, 2022
Kopra EI, Ferris JA, Rucker JJ, McClure B, Young AH, Copeland CS, Winstock AR.   +6 more
europepmc   +1 more source

Lysergic Acid Diethylamide (LSD): a report on its effects and psychotherapeutic use

, 1965
Lysergic acid diethylamide, LSD, was accidentally discovered by Dr. Albert Hofmann in 1943 while he was working as a research chemist for Sandoz Laboratories.
Abell, John Minor
core  

Distortions of Vision and Pain: Two Functional Facets of D-Lysergic Acid Diethylamide

, 1979
D-lysergic acid diethylamide (LSD) produces distortions of visual perception and analgesia. Evidence is advanced from a functional standpoint that the observed visual effects result from an attenuation of light-evoked input to the dorsal lateral ...
John Michael Williams
core   +1 more source

Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. [PDF]

Neuropsychopharmacology, 2022
De Gregorio D, Inserra A, Enns JP, Markopoulos A, Pileggi M, El Rahimy Y, Lopez-Canul M, Comai S, Gobbi G.   +8 more
europepmc   +1 more source

[[alternative]]Determination of 3,4-Methylenedioxymethamphetamine and Lysergic Acid Diethylamide in Urine by Capillary Electrophoresis/Fluorescence Spectroscopy

, 2010
[[abstract]]3,4-methylenedioxyamphetamine (3,4-MDMA) is a strong central nervous system stimulant. Using nonaqueous capillary electrophoresis/fluorescence detection, the precision of the method was evaluated by measuring the repeatability and ...
Ching Fang, [[author]]方晴, [[author]]Ching Fang, 方晴   +3 more
core  

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders

Pharmaceuticals
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs).
Tamara Valdez, Valbhi Patel, Nattaphone Senesombath, Zayd Hatahet-Donovan, Mary Hornick   +4 more
doaj   +1 more source

Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish

Scientific Reports
The therapeutic use of lysergic acid diethylamide (LSD) has resurfaced in the last decade, prompting further scientific investigation into its effectiveness in many animal models.
Ethan V. Hagen, Melike Schalomon, Yanbo Zhang, Trevor J. Hamilton   +3 more
doaj   +1 more source

125I-lysergic acid diethylamide binds to a novel serotonergic site on rat choroid plexus epithelial cells

, 1985
125I-Lysergic acid diethylamide (125I-LSD) binds with high affinity to serotonergic sites on rat choroid plexus. These sites were localized to choroid plexus epithelial cells by use of a novel high resolution stripping film technique for light ...
PR Hartig, KA Yagaloff
core   +1 more source